Eli Lilly’s next‑generation triple‑agonist, retatrutide, delivered unprecedented weight loss in late‑stage testing while prompting new tolerability scrutiny. Company and trial reports show high‑dose cohorts averaged weight reductions near 28–29% at readouts up to 68 weeks, alongside higher-than-expected discontinuation rates and skin adverse events in some participants. Results were presented across multiple trial disclosures and coverage at major industry meetings. Clinicians and investors are parsing efficacy versus safety: the magnitude of weight loss resets benchmarks for obesity therapeutics, but discontinuations and side‑effect profiles invite closer regulatory and payer scrutiny. Analysts note the data will reshape trial design and competitive positioning for GLP‑1 and multi‑agonist developers. Sponsors signaled further analyses and subgroup readouts are forthcoming.